作者: Scott D. Solomon , Brian Claggett , Akshay S. Desai , Milton Packer , Michael Zile
DOI: 10.1161/CIRCHEARTFAILURE.115.002744
关键词:
摘要: Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients heart failure (HF) and...